Pharvaris
Zug, Switzerland · Biotechnology, Health Care, Therapeutics · 126 employees
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise acr
Funding history
- Funding Round — $201.2M — Jul 2025
- Funding Round — $70.0M — Jun 2023
- Series series c — $80.0M — Nov 2020
Recent signals
- Jul 25, 2025: Raised $201.2M
- Nov 15, 2023: Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
- Jun 20, 2023: Raised $70.0M
- Nov 18, 2020: Raised $80.0M in Series series c
See plans & pricing → Track Pharvaris’s funding, hiring, and signals — with verified contacts — on Fundz.